Role of quantitative p16(INK4A) mRNA assay and digital reading of p16(INK4A) immunostained sections in diagnosis of cervical intraepithelial neoplasia by Vasiljevic, N et al.
1 
 
Role of quantitative p16INK4A mRNA assay and digital reading of p16INK4A 
immunostained sections in diagnosis of cervical intraepithelial neoplasia 
Short title: p16 mRNA aiding diagnosis of CIN2+ 
Nataša Vasiljević1, Paul D. Carter2, Caroline Reuter1, Rhian Warman1, Adam R Brentnall1, James R. 
Carton3, Jack Cuzick1, Attila T. Lorincz1§  
1. Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Barts and The London 
School of Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK 
2. Centre for Molecular Pathology, Royal Marsden Hospital, Downs Road, Sutton, SM2 5PT, UK 
3. Department of Histopathology, Charing Cross Hospital, Fulham Palace Road, London, W6 8RF, UK 
§Corresponding author: Attila T Lorincz, Centre for Cancer Prevention, Wolfson Institute of 
Preventive Medicine, Barts and The London School of Medicine, Queen Mary University of London, 
Charterhouse Square, London EC1M 6BQ, UK; Tel.: 020-7882-3540; Fax: 020-7882-3890; E-mail: 
a.lorincz@qmul.ac.uk 
Key Words: p16 RT-qPCR, p16 Immunohistochemistry, digital H-score, human papilloma virus, 
cervical intraepithelial neoplasia 
Abbreviations:  
AUC Area under curve 
CIN Cervical intraepithelial neoplasia 
IHC Immunohistochemistry 
HPV Human papilloma virus 
LLETZ Large loop excision of the transformation zone  
2 
 
p16 p16 INK4A protein 
RT-qPCR Real time quantitative polymerase chain reaction 
Appropriate category: Tumor Markers and Signatures  
Novelty and Impact:  
We present two novel approaches to aid diagnosis of CIN2/3, based on either quantitative PCR, 
measuring p16 mRNA levels, or digitalised reading of immunohistochemical p16 protein staining. 
The main strength of these tests is their objectivity which may improve diagnosis of cervical 
intraepithelial neoplasia in locations with a lack of skilled pathologists. Furthermore, the application 







Visual interpretation of cervical biopsies is subjective and variable, generally showing fair to 
moderate inter-reader agreement in distinguishing high from low grade cervical intraepithelial 
neoplasia (CIN). We investigated the performance of two objective p16 quantitative tests in 
comparison with visual assessment: 1) p16-mRNA assay and 2) digital analysis of sections stained for 
p16 protein.  
The primary analysis considered 232 high-risk HPV+ samples from diagnostic cervical specimens. A 
p16 RT-qPCR (p16-mRNA assay) was run on mRNA extracted from formalin-fixed paraffin-embedded 
sections. Two p16 immunohistochemistry (IHC) readings, a visual read by a histopathologist (Visual 
IHC) and a digital read of a high-resolution scan (Digital IHC), were done on adjacent sections. The 
worst reviewed CIN grade (agreed by at least two histopathologists) from up to two biopsies and a 
loop excision was taken, with CIN2/3 as the primary endpoint. 
Visual IHC attained a specificity of 70% (95%CI 61-77) for 85% (95%CI 77-91%) sensitivity. The four-
point Visual IHC staining area under the curve (AUC) was 0.77 (95%CI 0.71-0.82), compared with 0.71 
(95%CI 0.64-0.77) for p16-mRNA and 0.67 (95%CI 0.60-0.74) for Digital IHC. Spearman rank-order 
correlations were: visual to p16-mRNA 0.41, visual to digital 0.49 and p16-mRNA to digital: 0.22. The 
addition of p16-mRNA assay to visual reading of p16 IHC improved the AUC from 0.77 to 0.84 
(P=0.0049) 
p16-mRNA testing may be complementary to visual IHC p16 staining for a more accurate diagnosis of 





Infection by high risk human papilloma virus (hrHPV) and subsequent failure to attend for cervical 
screening are the principal factors responsible for high cervical cancer burden. After host exposure 
to HPV, the virus may become established in tissues as one or more areas of normal-appearing 
epithelium which over time remain visually flat or perhaps assume warty features. In early stages of 
HPV infection, the histopathological examination of biopsies usually appears morphologically 
normal. They might, however, have various minor changes or sometimes show architecture 
consistent with cervical intraepithelial neoplasia grade 1 (CIN1). Over a period of years persistent 
hrHPV infection can transform the affected tissue into high grade intraepithelial disease, either CIN2 
or the more worrisome CIN3, which are regarded as precancerous lesions [1, 2].  
hrHPV infections and associated low grade lesions are quite common, but almost all spontaneously 
clear within a few years [3-6]. Depending on specific diagnostic criteria, expertise of the pathologist 
and level of surveillance an estimated 50% of CIN2 may regress without intervention [7]. The 
regression rate of CIN3 is incompletely assessed due to ethical considerations, but it is believed that 
a small percentage of CIN3 ever become invasive [8, 9]. Since the 1960s, in most countries of Europe 
and North America, cytological screening programmes have been implemented with 3 to 5 yearly 
screening intervals starting in a woman’s mid-twenties. Women with moderate or severe dysplasia 
on cytology (also called HSIL) as well as hrHPV-positive women with mild or borderline abnormal 
findings (also called LSIL or ASCUS) are referred to colposcopy [10]. Some countries are also making 
the transition to use HPV testing as a primary screen [11]. The decision on who receives preventative 
excision treatment is predominantly based on a pathologist’s CIN grading of biopsies collected 
during colposcopy, CIN2 being the most commonly set threshold for intervention [12]. Although the 
success of this approach is indisputable [13], it is difficult to implement effectively in low-resource 
settings. Morphological screening and grading methods are subjective and prone to variability with 
CIN3 and cancer shown to be the most, and CIN2 the least, reproducible diagnosis [14, 15]. This 
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might lead to unnecessary treatment, which is a concern due to the potential harm to patients and 
from a monetary perspective. After treatment, women commonly experience substantial pain and 
discomfort for weeks, however, the main morbidity of treatment is subsequent cervical insufficiency, 
leading to a higher risk of 2nd and 3rd trimester miscarriage and preterm delivery [16]. Biomarkers 
that improve triage of women to colposcopy and provide for a more accurate diagnosis of CIN3 
destined to progress are therefore highly desirable. 
Elevation of p16 INK4A protein, henceforth denoted as p16, in HPV-positive women may indicate a 
high-grade lesion with increased risk of development to cancer [17, 18]. p16 would normally be 
suppressed by retinoblastoma protein (pRb), however if a hrHPV infection persists, a continuous 
expression of the E6 and E7 oncoproteins inactivate p53 and pRb leading to p16 overexpression. p16 
overexpression may therefore be considered a surrogate marker of persistent HPV infection and 
measurement of its expression allows triage of a higher risk group of hrHPV-positive women to 
colposcopy [19].  In addition, co-reading of p16 and hematoxylin and eosin (H&E) stained biopsies 
has been shown to improve observer agreement in the diagnosis of CIN [20, 21].  The reported 
sensitivity of p16 immunohistochemistry (IHC), however, varies due to difficulties in reproducible 
reading of the slides, lack of standardised reporting, and uncertainty about the best cut-off point. 
Detecting the presence of p16 mRNA by a molecular test rather than staining biopsy sections for the 
presence of the protein could diminish the subjectivity of p16 testing. In this study, we explore the 
potential of a novel real time (RT)-qPCR assay for measuring p16 mRNA expression to improve 
grading of CIN lesions in a set of formalin-fixed paraffin-embedded (FFPE) cervical biopsies from a UK 
colposcopy referral population [22]. As a comparison of performance, we also used p16 IHC staining 
graded by both an expert histopathologist (Visual IHC) and analysed as an H-Score by an automated 




Materials and Methods 
Patients 
The Predictors 2 study comprised 1,099 women referred for colposcopy in London between 
September 2007 and October 2009 following an abnormal cytology result [22]. Women attended 
one or two colposcopies. For the current study, p16 testing was performed on 287 biopsy specimens 
that were available from the first colposcopy visit (Figure 1). Some women were recalled for a 
second colposcopy and additional biopsies taken where abnormalities were seen. None of the 
second biopsies were used for p16 testing. Women who met the standard UK criteria for treatment 
were referred to an expert clinic for large loop excision of the transformation zone (LLETZ). LLETZ 
tissues as well as second biopsies had histopathological review data available which was considered 
for the final reference diagnosis in the current study. However, the three p16 tests investigated here 
were done only on the first biopsies. All women in Predictors 2 received a patient information sheet 
explaining the study and provided written consent. Approvals were obtained from the relevant local 
research ethics committees.  
Histopathological Diagnosis 
In our main analyses, we dichotomized the specimens into a set with the diagnosis of CIN2 or CIN3 
(CIN2/3) versus the set with a normal or CIN1 (<CIN2) reference diagnosis. However, additional 
diagnostic categories were provided by the pathologists and used in some of our secondary 
analyses. For the Predictors 2 study, H&E stained sections of all study specimens were read by the 
routine hospital pathologist(s) and reviewed by an expert consultant pathologist. In case of 
disagreement, diagnosis was arbitrated by a second expert pathologist [22]. The worst reviewed 
histology of the second biopsies and LLETZ were retrieved from Predictors 2 study. For the present 
study, the first biopsies were reviewed by a different histopathologist (JRC). To maximise the 
likelihood of accurate diagnosis, the worst reviewed histology of the first biopsy was based on JRC 
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review and Predictors 2 expert consultant pathologist, while hospital grading was used to arbitrate 
(Supplemental methods). The worst concordant diagnosis on any biopsy (first, second and if 
available the LEETZ surgical specimen) was used to determine the final reference diagnosis for 
comparisons of the p16 tests. 
 HPV testing 
HPV status of the 287 patients was determined in the Predictors 2 study by Hybrid Capture 2 HPV 
test (Qiagen, Hilden, Germany) and the BD HPV test (Becton Dickinson Diagnostics, Sparks, 
Maryland, USA) on exfoliated cervical cells from the concurrent sample [22]. hrHPV positive samples 
were defined as specimens positive by either of these two tests. 
p16 immunohistochemistry for visual and digital reading 
Two 5 µm sections were cut from the FFPE first biopsy blocks for H&E and p16 IHC staining. p16 IHC 
was done using the CINtec p16 Histology assay (Ventana, Tucson, AZ USA) according to the 
manufacturer’s instructions. The histopathologist (JRC) performed the visual p16 readings, hence 
referred to as Visual IHC, and was blinded to all patient data. Visual IHC was scored using a semi-
quantitative scale with four categories: normal, sporadic, focal or diffuse [23]. Diffuse staining was 
the cut-off point for calling specimens positive [21]. The p16 stained sections were also scanned 
using a Panoramic 250 digital slide scanner (3D Histech Kft, Budapest, Hungary). The images were 
analysed using the Nuclear Quant module (version 1.15.1.9) from which the H-score (3 x percentage 
of strongly staining nuclei + 2 x percentage of moderately staining nuclei + percentage of weakly 
staining nuclei, giving a range of 0 to 300) was obtained, hence referred to as Digital IHC. 
p16-mRNA Assay  
Six 10µm sections from the first biopsies were cut directly into 1.5 ml microcentrifuge tubes and 
stored at -70°C.  The tissue sections were deparaffinised in 320µl of n-Hexadecane (Alfa Aesar, 
Heysham, UK) at 56°C for 3 minutes. Total RNA was extracted using the RNeasy FFPE Kit (Qiagen) 
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according to the manufacturer’s instructions. A Nanodrop 1000 spectrophotometer (Thermo Fisher 
Scientific, Waltham, MA, USA) was used to quantify RNA and up to 300 ng of DNase-treated total 
RNA was reverse transcribed using the QuantiTect Reverse Transcription Kit (Qiagen) according to 
the manufacturer’s instructions. A region of the gene RPLP0 was selected after optimisation 
experiments as the reference gene. For this test, equal amounts of mRNA from 20 samples were 
tested on six housekeeping genes obtained from Qiagen: RPLP0 (Cat. no. QT00075012), ACTB (Cat. 
no. QT00095431), B2M (Cat. no. QT00088935), GAPDH (Cat. no. QT01192646), HPRT1 (Cat. no. 
QT00059066), PGK1 (Cat. no. QT00013776). RPLP0 showed the most stable expression (data not 
shown). Further, p16 (Cat. no. QT00089964) and RPLP0 primers were tested for amplification 
efficiency and specificity using a 10-fold dilution of Stratagene QPCR Human Reference Total RNA 
(Agilent Technologies, Santa Clara, CA, US) and melt curve analysis. Measurement of p16 expression, 
thereafter called p16-mRNA assay, was performed on a Rotor-Gene 6000 (Qiagen) with the following 
cycling conditions: 95°C for 5 min, then 40 cycles of 5 s at 95°C and 10 s at 60°C with a final melting 
curve measuring step from 60 to 99°C. Two microliters (~25 ng) cDNA was amplified in a volume of 
25 µl containing Rotor-Gene SYBR Green PCR master mix (Qiagen) and 1X dilution of p16 or RPLP0 
primer as per manufacturer’s instructions. Each sample was run in duplicate and the average Ct 
value was calculated. qPCR runs included a four points standard curve, a No-RT control and a No 
Template Control in duplicate for both primers. Any sample with a Ct value for RPLP0 greater than 
24 was excluded from the analysis due to insufficient amount of cDNA. 
Statistical Analyses 
The expression stability of the reference genes was determined using BestKeeper (version 1) 
software [24]. The relative expression of p16 was calculated using the ΔΔCt method [25]. Fold 
expression of p16 in CIN1, CIN2 and CIN3 was analysed in relation to the median expression in 
normal biopsies. A Cuzick test for trend and a Mann-Whitney U test were used to look for significant 
differences in p16 expression stratified by diagnostic groups. Agreement between the 
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histopathologist reviews was explored with Cohen’s Kappa statistics. Correlations were investigated 
by Spearman rank correlation coefficient. Logistic regression was applied to determine if p16 
methods in combination performed better than Visual IHC alone in the first biopsy to predict the 
reference diagnosis and DeLong confidence intervals for area under the curve (AUC) statistics were 
obtained. Statistical analyses used GraphPad Prism software (v5.03), Stata v11.2, and R [26]. A 
statistical test was accepted as significant if the two-sided P value was <0.05.   
Results 
p16 expression 
Expression of p16 was successfully measured in 280 of 287 biopsies (Figure 1) and a trend of 
increasing p16-mRNA level was observed with increasing lesion severity χ21= 45.5 (p<0.0001, Figure 
2). There was only one HPV negative patient diagnosed with CIN2+ and the p16-mRNA level in this 
woman was low, comparable to the women with a normal diagnosis (Figure 2). Generally, a 
significantly higher level of p16 expression was observed in HPV positive women compared to HPV 
negative women with a 7.2-fold difference observed between the HPV negative and HPV positive 
CIN1 groups (p=0.007, Figure 2).  
Agreement between histopathological reviews 
The agreement between the pathologists on the first biopsy, where all specimens were read by the 
two study experts and hospital pathologist(s) for <CIN2 versus CIN2/3, was overall fair to good with 
Kappas of 0.62 (95%CI 0.51-0.73), 0.78 (95%CI 0.69-0.87) and 0.64 (95%CI 0.54-0.75) for the pairwise 
comparisons (Supplemental tables 1-3). Agreement was, however, poor if all diagnostic categories 
were taken under consideration, with Kappas of 0.27 (95%CI 0.17-0.37), 0.37 (95%CI 0.28-0.46) and 
0.43 (95%CI 0.34-0.53) (Supplemental table 1-3).  
Comparisons of p16 measures in hrHPV samples 
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Performance of the three p16 assays was analysed in 232 hrHPV positive patients (Figure 1). The 
summary statistics of the two quantitative tests were overviewed in the 232 patients (Supplemental 
table 4). The association observed between p16-mRNA and Digital IHC was weak (Spearman rank 
correlation 0.22, p=0.0009, Figure 3a). There was a modest but significant association between the 
p16-mRNA assay and Visual IHC (Spearman rank correlation 0.41, p<0.0001, Figure 3b), as well as 
between Digital and Visual IHC (Spearman rank correlation 0.49, p<0.0001, Figure 3c).  
Diffuse staining based on Visual IHC had a sensitivity at 85% (95%CI 77-91%) and specificity 70% 
(95%CI 61-77%) (Table 1).  
The four-point Visual IHC staining area under the curve (AUC) was 0.77 (95%CI 0.71-0.82), 
compared with 0.71 (95%CI 0.64-0.77) for p16-mRNA assay and 0.67 (95%CI 0.60-0.74) for Digital 
IHC (Figure 4, Supplemental Figure 1). The Visual IHC combined with the p16-mRNA assay 
significantly improved the diagnostic accuracy from AUC=0.77 for Visual IHC alone to AUC=0.84 
(p=0.0049) for the combination test. In contrast, Digital IHC did not significantly improve the AUC of 
the Visual IHC test (p=0.21) (Table 2 and Figure 4). A combination of p16-mRNA and Digital IHC also 
improved the ability to detect CIN2/3 compared with either test alone (AUC = 0.76, ΔLR-χ2= 13.8, 
p<0.0002; c.f. Figure 3). 
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 Discussion  
This is the first study to measure p16-mRNA levels and utilise an automated computer-generated H-
score from digitally scanned images of p16 IHC stained cervical biopsy sections. The performance of 
these two tests for identifying high grade intraepithelial disease was assessed in comparison with 
expert visual reading of p16 IHC staining patterns. The aim of the study was to determine the 
performance of the two quantitative p16 tests univariately and in combination with the Visual IHC 
results. While p16 staining of biopsies has been shown to improve inter-reader reliability [20, 21], 
this standard method requires a subjective visual interpretation by a trained morphologist. 
Therefore, objective quantitative methods, such as those investigated here, could complement the 
expert pathologist H&E reading in routine practice. An objective p16 test would be particularly 
useful in low to middle-income regions where there may be a lack of sufficiently trained 
pathologists. We show that p16-mRNA has the potential to improve the visual diagnosis based on 
H&E interpretation plus p16 visual scoring and may lead to a more accurate approach to diagnosing 
CIN2/3 (Figure 4).  
We based our study on a colposcopy referral population to increase power for the endpoint of 
interest (CIN2/3). Only 287 of the first biopsies collected for the Predictor 2 cohort were available for 
p16 testing (Figure 1), limiting the study to be conducted without a power calculation. However, 
despite that these samples were a convenience set, they were similar to the percentage of the 
histological grades seen in the complete colposcopy population. The original biopsies were read by 
the hospital histopathology team and the sections were subsequently reviewed by two expert 
histopathologists. Dichotomization of the data at a cut-off relevant to the decision to treat or not 
(<CIN2 and CIN2/3), showed good agreement on H&E readings between the histopathologists. 
However, taking into consideration all diagnostic categories, the agreement was poor (Supplemental 
tables 1-3). In our study a trend of the expert reviewers downgrading low grade lesion diagnoses 
was observed, an occurrence that has previously been reported [27]. Comparing the relative 
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performance of the three p16 approaches tested here, the Visual IHC interpretation with diffuse 
staining as the cut-off [21] yielded the best results (Table 1 and Figure 4). Other studies based on 
visual interpretation of p16 staining have shown similar sensitivity and specificity to our study [28, 
29]. The novel p16-mRNA assay performed similarly to the Visual IHC and, at 90% sensitivity, the 
specificity observed for the mRNA assay was not different than for Visual IHC (Figure 4). In addition, 
logistic regression suggested that complementing p16 Visual IHC reading with a p16-mRNA assay 
could significantly improve accuracy of diagnosis from an initial AUC of 0.77 to an AUC of 0.84 
(p=0.0049) (Table 2 and Figure 4).  The Digital IHC had the weakest performance of all the tests 
(Figure 4 and Supplemental Figure 1). To the best of our knowledge, this utilisation of H-score for 
p16 expression has not been investigated before.  Although such a digital test would avoid the 
drawback of working with mRNA, a requirement of the p16-mRNA assay, the scanning equipment is 
quite expensive and would therefore also be less likely to be applicable in low income regions than 
use of an inexpensive PCR test. 
There was a significant increase in expression of p16 (p <0.0001) in CIN2/3 compared to <CIN2 
biopsies (Figure 2), an observation supported by the previous reports that expression of p16 is 
elevated in higher grade lesions [17, 18]. As there was only one HPV negative CIN2+, no meaningful 
comparison could be done in this group. The HPV negative CIN1 lesions had significantly lower p16 
expression than the HPV positive CIN1 lesions (P=0.007) as would be expected due to lack of HPV 
interference with the p16 pathway.  
Our study has several novel features including the comparisons of the p16-mRNA assay and the 
digitally read H-score to each other and to the visual readings. Although there have been some 
earlier studies of p16 expression using RT-qPCR in cervical specimens, all have been on small 
underpowered sample sets. Upregulation of p16 at both the mRNA and protein level in a small 
number of carcinomas and cell lines compared to normal tissue was reported in one study [30], 
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while another reported a 6-fold increase in p16 mRNA expression in high-grade cytology specimens 
compared to normal cells and HPV-negative women [31].  
An important limitation of our study was that it was performed on biopsy specimens and there were 
no comparisons to corresponding exfoliated cervical cells. Unfortunately, a pilot study found that the 
quality of RNA was too poor in this archived material to obtain valid RT-qPCR measurements (data 
not shown). The measurement of p16-mRNA levels in exfoliated cervical specimens deserves further 
attention in studies designed to address the mRNA instability problem. It is possible that a 
combination of p16-mRNA with other biomarkers such as DNA methylation in exfoliated cell 
specimens may provide a substantially improved triage test for reducing the number of women 
requiring referral to colposcopy.   
In conclusion, we present two novel approaches, a p16-mRNA assay and digital reading of p16 IHC, 
to aid the objective diagnosis of CIN2/3. Application of these measures in a triage test might help to 
avoid unnecessary treatment in HPV-positive women. Visual interpretation of p16 IHC is likely to be 
the best available method, but our data show that use of a p16-mRNA assay may be complementary 
and improve the accuracy of the diagnosis. We also envisage the possibility of a future biomarker 
panel including p16-mRNA in settings where the diagnostic emphasis is on nucleic acid testing. 
Analysis of p16 levels alone or in combination with other biomarkers, shows promise to improve 
diagnosis of cervical intraepithelial neoplasia in locations with a lack of skilled pathologists.  
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Table 1. The sensitivity and specificity of the Visual p16 IHC for CIN2/3 or CIN3 using combinations of 
the scoring categories, diffuse (D), focal (F), Sporadic (S) as the cut off.  
 
 Cut off Positive tests 
(Number) 
Sensitivity  Positive tests 
(Number) 
Specificity 
 CIN2/3      
 D 85 0.85 (95%CI 0.77-0.91) 40 0.70 (95%CI 0.61-0.77) 
 D+F 88 0.88 (95%CI 0.80-0.93) 69 0.48 (95%CI 0.39-0.56) 
 D+F+S 90 0.90 (95%CI 0.83-0.94) 84 0.36 (95%CI 0.29-0.45) 
CIN3      
 D 58 0.89 (95%CI 0.79-0.95) 40 0.70 (95%CI 0.61-0.77) 
 D+F 60 0.92 (95%CI 0.83-0.97) 69 0.48 (95%CI 0.39-0.56) 




Table 2. Performance summary of the three tests. The combined AUC is for Visual with the 
quantitative measures fitted using a logistic regression.  








Addition to Visual IHC 
(p-value) 
CIN2/3 Visual IHC 74.9 <0.0001 0.77 (0.71-0.82)    
p16-mRNA 31.8 <0.0001 0.71 (0.64-0.77) 0.84 7.9 0.0049 
Digital IHC 21.5 <0.0001 0.67 (0.60-0.74) 0.81 1.6 0.21 
CIN3 Visual IHC2) 66.8 <0.0001 0.77 (0.71-0.82)    
p16-mRNA 26.3 <0.0001 0.71 (0.64-0.79) 0.85 7.4 0.0064 
Digital IHC 28.3 <0.0001 0.73 (0.65-0.80) 0.84 4.7 0.029 
1) Likelihood ratio- chi square 
2) Univariate LR-χ2 is on 4df for Visual, and 1df for RT-qPCR and IHC digital. 
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Figure.1 Flowchart showing the number of valid tests results for the women selected for the study. 
Figure 2. p16-mRNA expression fold-difference in the first biopsies of 280 women stratified by worst 
reviewed histology and HPV status. Fold expression in CIN1, CIN2, CIN3 is shown in relation to the 
median expression of 48 normal biopsies. The Cuzick trend test confirmed a significant increasing 
trend (p<0.0001) with lesion severity in HPV positive women. Higher p16 expression was observed in 
CIN1 women who were HPV positive compared to HPV negative (p=0.007).  
Figure 3. Comparison between three p16 measures. (a) p16 mRNA assay (RT-qPCR) vs Digital IHC 
(IHC digital), (CIN2+  +; < CIN1 circle); (b) p16-mRNA assay vs Visual IHC staining categories (Visual; 
N=Normal, S=Sporadic, F=Focal; D=Diffuse; grey=CIN2+, white = < CIN2); (c) Digital IHC vs Visual IHC 
staining categories (same format as (b)).  
Figure 4. The performance of the different tests to detect CIN2/3 visualised with univariate ROC 
curves. The circles present the categorical visually read p16 IHC data from Table 1 where the cut offs 
are based on D (diffuse), D+F (D+focal) and D+F+S (D+F+sporadic) staining.   
 
